Spawned by Yale University, biotech company 3PrimiR Inc., which is focused on applying microRNA discoveries to cancer diagnostics, has raised $2 million in a planned $4 million equity financing, according to federal documents.
According to the website of Yale’s Office of Cooperative Research, Westport, Conn.-based 3PrimiR was founded by Yale scientists based on their discoveries of the predictive roles of mutations affecting microRNA in cancers. The filing with the U.S. Securities and Exchange Commission notes the two company executives as Barbara Mignogna-Korus and Andrew Weidhaas. (read more)
Subscribe to the miRNA blog
Thank you for subscribing.
Something went wrong.
